Iowanews Headlines

Global KRAS Inhibitors Market

The KRAS Inhibitors market across the seven major markets (7MM), the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is anticipated to witness robust growth over the next decade. Valued at approximately USD 526 million in 2025, the market is projected to reach USD 7,847 million by 2034, expanding at an impressive CAGR of 35% during the forecast period (2024–2034).

The United States is expected to remain the dominant contributor, accounting for nearly 70% of the total KRAS inhibitors market share in 2024 and maintaining its leadership throughout the forecast period. Among the EU4 and the UK, Germany represents the largest market, while Spain accounted for the smallest share in 2024.

KRAS (Kirsten Rat Sarcoma viral oncogene) is the most frequently mutated of the three RAS genes, followed by NRAS and HRAS. Mutations in KRAS are commonly linked with several aggressive cancers, including pancreatic, colorectal, lung adenocarcinomas, and ovarian cancers, among others. These mutations often drive uncontrolled cell proliferation and resistance to conventional therapies, creating a strong need for targeted treatment options.

The recent approvals of KRAS G12C inhibitors, such as sotorasib and adagrasib, have marked a transformative shift in oncology, paving the way for the development of next-generation KRAS-targeted therapies. Ongoing research efforts are expanding beyond G12C mutations, focusing on other variants such as G12D and G12V, which could further broaden the therapeutic landscape.

Overall, the KRAS inhibitors market is poised for exponential growth through 2034, driven by increased mutation testing, novel drug development, and combination therapy strategies. As precision oncology continues to advance, KRAS-targeted therapies are expected to play a pivotal role in reshaping the treatment paradigm for multiple solid tumors.

DelveInsight’s report, “KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the KRAS Inhibitors landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines KRAS Inhibitors market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

Some of the key facts of the KRAS Inhibitors Market Report:

• The leading KRAS Inhibitors Companies developing therapies include Amgen, Verastem Oncology, Revolution Medicines, Roche, Eli Lilly and Company, and others.

• Potential future therapies for KRAS Inhibitors include LUMAKRAS, KRAZATI, AVMAPKI + FAKZYNJA Co-Pack, Divarasib, D3S-001, BDTX-4933, and others.

• The future of KRAS Inhibitors treatment holds promise, driven by ongoing research and the development of innovative therapies. Current management strategies, such as symptomatic medications, physical therapy, and supportive care, remain essential.

KRAS Inhibitors Overview

KRAS is a member of the RAS superfamily, a group of small GTP-binding proteins also known as RAS-like GTPases. The RAS oncogene, originally identified in the rat sarcoma virus, acts as a crucial signal transducer that regulates cell growth, differentiation, and survival in both normal and malignant cells. Among the various signaling cascades, the RAS–RAF–MEK–ERK pathway is one of the most extensively studied, and its dysregulation is frequently associated with the onset and progression of multiple cancer types.

KRAS mutations refer to genetic alterations in the KRAS gene, which encodes a key protein involved in intracellular signaling. These mutations are commonly observed in cancers such as colorectal cancer (CRC), lung cancer, and pancreatic cancer. Historically, KRAS mutations have been considered “undruggable” due to the protein’s structural complexity, making it difficult to design effective inhibitors. However, recent research breakthroughs have enabled the development of promising KRAS-targeted therapies, though their current application remains largely confined to non-small cell lung cancer (NSCLC).

The management of KRAS-mutated cancers typically involves a multimodal approach, including surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy. In selected cases, particularly for patients with small peripheral lung tumors who are not suitable for surgery, radiofrequency ablation (RFA) may also be considered as a therapeutic option.

Learn more about KRAS Inhibitors treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ KRAS Inhibitors Treatment Market

Key Factors Driving Growth in the KRAS Inhibitors Market

• Broad and Addressable Patient Pool Across Solid Tumors: Among the three RAS genes, KRAS, NRAS, and HRAS-KRAS is the most frequently mutated. These mutations are widely observed across several solid tumors, including pancreatic, colorectal, lung adenocarcinoma, and ovarian cancers, among others. Within the 7MM, the United States accounts for the largest share of KRAS-mutated NSCLC cases, representing approximately 46% of all such cases in these markets.

• Rising Potential of Combination Treatment Strategies: Integrating KRAS-targeted therapies with existing treatment approaches such as immunotherapy and chemotherapy offers significant potential to enhance clinical outcomes. The development of combination regimens not only improves therapeutic efficacy but also opens new market opportunities, reinforcing the overall growth prospects of the KRAS inhibitors landscape.

• Emerging Growth in the Pan-KRAS Therapeutic Segment: Several leading biopharmaceutical companies are actively pursuing pan-KRAS inhibitors capable of targeting multiple KRAS mutation types. Key players such as Cardiff Oncology (onvansertib), Immuneering Corporation (IMM-1-104), Jacobio Pharma (JAB-23E73), and Eli Lilly (LY4066434) are expected to drive substantial market expansion by addressing a broader patient base across diverse tumor types.

• Progress in Targeting Multiple Mutation Subtypes and Cancer Types: Companies including Roche, Revolution Medicines, and Eli Lilly are advancing a new generation of KRAS inhibitors, notably divarasib, daraxonrasib, and olomorasib, to broaden therapeutic coverage across different mutation subtypes and tumor categories. These advancements signify a major step forward in refining precision oncology and improving treatment outcomes for patients with KRAS-driven cancers.

Recent Developments in KRAS Inhibitors Clinical Trials:

• In May 2025, Verastem Oncology received U.S. FDA approval for the AVMAPKI + FAKZYNJA CO-PACK (a combination of avutometinib capsules and defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have undergone prior systemic therapy. This marks the first and only FDA-approved therapy for this indication. The approval was granted under the accelerated approval pathway, based on tumor response rate and duration of response (DoR) data.

• In April 2025, Bristol Myers Squibb (BMS) announced upcoming Phase III trial milestones from its KRYSTAL clinical program — with KRYSTAL-10 (for second-line colorectal cancer) expected to report results in 2026, KRYSTAL-7 (for first-line NSCLC with PD-L1 ≥50%) anticipated in 2028, and KRYSTAL-4 (for first-line NSCLC) projected for 2029.

• In January 2025, Sotorasib (Lumakras) received a new FDA approval in 2025 as part of a combination regimen with panitumumab for adults with KRAS G12C–mutated metastatic colorectal cancer who have received prior chemotherapy.

Learn more about the recent advancements in KRAS Inhibitors treatment landscape @ KRAS Inhibitors Recent Developments

KRAS Inhibitors Epidemiology

• Among the analyzed cancer types, colorectal cancer (CRC) accounts for the highest number of KRAS-mutant cases, followed by pancreatic cancer, non-small cell lung cancer (NSCLC), and low-grade serous ovarian cancer (LGSOC). In the United States, approximately 66,000 cases of KRAS-mutant CRC were reported in 2024.

• The KRAS G12C mutation is the most prevalent variant in NSCLC, whereas the G12D mutation is the dominant variant observed in CRC, pancreatic cancer, and LGSOC. In the U.S., KRAS G12C mutations are detected in roughly 37% of NSCLC cases, while KRAS G12D mutations occur in about 42% of pancreatic cancers, 30% of CRCs, and 42% of LGSOC cases, respectively.

KRAS Inhibitors Epidemiology Segmentation

• Total incident cases of NSCLC, CRC, pancreatic cancer, and LGSOC

• Total KRAS incident cases in NSCLC, CRC, pancreatic cancer, and LGSOC

• Total KRAS variant cases in NSCLC, CRC, pancreatic cancer, and LGSOC

KRAS Inhibitors Marketed Drugs

• KRAZATI (adagrasib): Bristol Myers Squibb (Mirati Therapeutics)

• LUMAKRAS/LUMYKRAS (sotorasib): Amgen

KRAS Inhibitors Emerging Drugs

• Olomorasib (LY3537982): Eli Lilly and Company

• MK-1084: Merck, Taiho, and Astex Pharmaceuticals

KRAS Inhibitors Market Barriers

• Limited Mutation Coverage: Currently approved KRAS inhibitors, such as those targeting the G12C mutation, only address a small subset of KRAS-mutated cancers. Other prevalent mutations like G12D, G12V, and G13D remain largely untargeted, limiting the overall patient population that can benefit from existing therapies.

• Development of Drug Resistance: Resistance mechanisms, both primary and acquired—pose a major obstacle to sustained efficacy. Tumor cells often develop adaptive signaling pathways or secondary KRAS mutations, reducing the long-term therapeutic benefit of KRAS inhibitors.

• Tumor Heterogeneity and Complexity: The biological diversity across tumor types and mutation subtypes complicates treatment response and drug development. Variability in tumor microenvironments and co-occurring genetic alterations often influences sensitivity to KRAS-targeted therapies.

Request a free sample copy or view report summary: KRAS Inhibitors Market Report

Scope of the KRAS Inhibitors Market Report:

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key KRAS Inhibitors Companies: Amgen, Verastem Oncology, Revolution Medicines, Roche, Eli Lilly and Company, and others

• Key KRAS Inhibitors Therapies: LUMAKRAS, KRAZATI, AVMAPKI + FAKZYNJA Co-Pack, Divarasib, D3S-001, BDTX-4933, and others

• KRAS Inhibitors Therapeutic Assessment: KRAS Inhibitors current marketed and KRAS Inhibitors emerging therapies

• KRAS Inhibitors Market Dynamics: KRAS Inhibitors market drivers and KRAS Inhibitors market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• KRAS Inhibitors Unmet Needs, KOL’s views, Analyst’s views, KRAS Inhibitors Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/